|
Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Business Market Research
Energy Market Research
Financial Market Research
Pharmaceutical Market Research
Telecoms Market Research
|
Home > Market Research > Prescription Medicines > The Pharmaceutical Market: Hungary
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Hungary is a landlocked country in central Europe. The population stands at 9.9 million in 2010, of whom 16.0% are aged 65 or over. Hungary is one of the ten countries that joined the EU in May 2004. EU Directives have been transposed into national legislation; Directive 2004/27/EC was implemented in November 2005.
Funding for healthcare in Hungary is managed by the National Health Insurance Fund Administration (NHIFA), which runs the only health insurance fund in the country. In February 2008, a new bill on health insurance was signed into law, which enabled private companies to buy shares in 22 new health funds. However, the legislation was repealed in May 2008 and the health funds are to be phased out.
Around 65% of the pharmaceutical market is supplied by imports. France, Germany and Switzerland were the leading suppliers in 2007, accounting for over 55% of imports. The value of imports has increased every year since 2001.
Sources of funding for pharmaceuticals include the pharmaceutical industry itself as drug companies have been forced to contribute part of their turnover to the Health Insurance Fund, in order to cover government overspending. The Pharma Economic Act, which came into force in January 2007, successfully prevented the drugs budget from running into deficit for the first time in over a decade. However, manufacturers have reported loss of profits since the enforcement of the Act.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel
Top of Page
Table of Contents
EXECUTIVE SUMMARY 1
Introduction 2
Pharmaceutical Market Analysis . 3
Size . 3
Market Structure . 3
Generics Sector 4
OTC Sector . 4
Projections & Outlook . 4
Imports 9
Domestic Manufacturing . 11
Trade Associations . 12
AIPM 12
MAGYOSZ . 12
Domestic Producers 13
Biogal . 13
Chinoin 13
Egis 14
Gedeon Richter . 16
Human . 22
ICN Magyarorszag (Alkaloida) 23
Keri Pharma . 23
Pharmavit 24
Exports 24
Research & Development . 25
Pharmaceutical Regulatory Analysis 26
Pharmaceutical Regulation . 26
EU Regulatory Reforms 26
Centralised procedure . 26
Mutual recognition procedure . 26
Pharmaceutical Registration . 27
Advertising 28
Pricing & Reimbursement . 28
Decree 17/2007 . 28
Price freezing and the Pharma Economic Act 29
Intellectual Property 30
Pharmaceutical Distribution 30
Wholesaling 30
HUNGARY PHARMA OUTLOOK
Pharma Outlook espicom BUSINESS INTELLIGENCE
ii Quarter I 2010
Distributors 30
Hungaropharma . 30
Medimpex 31
Pharmafontana 31
Retailing 31
Healthcare Analysis 33
Demographics . 33
Population . 33
Birth Rate . 34
Death Rate 34
Infant Mortality . 34
Life Expectancy at Birth . 34
Public Health . 34
Causes of Death 34
Incidence of Communicable Diseases . 34
Incidence of Non-communicable Diseases 35
HIV/AIDS . 35
Healthcare System 35
National Health Fund Administration 36
Local Government . 36
Private Healthcare . 37
Healthcare Reform 37
Health Expenditure . 38
Healthcare Infrastructure 39
Inpatient Analysis 39
Healthcare Personnel . 40
DIRECTORY 41
Healthcare Organisations . 41
Trade Associations . 41
Methodology & Sources . 42
PHARMA OUTLOOK HUNGARY
Pharma Outlook espicom BUSINESS INTELLIGENCE
Quarter I 2010 iii
List of Tables
Summary of Key Data Projections, 2010-2015 . 2
Summary of the Hungarian Pharmaceutical Market, 2010 3
Per Capita Medicine Turnover by Area, 2006 . 3
Market Projections, 2010-2015 . 4
SWOT Analysis of the Hungarian Pharmaceutical Market, 2009 6
Espicom Analysis of the Hungarian Health Sector, 2010 7
Imports of Pharmaceuticals by Category, 2003-2007 (US$000s) 9
Import Trends, 2006-2007 (US$000s) 9
Leading Suppliers of Raw Materials, 2007 (US$000s) . 9
Leading Suppliers of Antisera & Vaccines, 2007 (US$000s) . 10
Leading Suppliers of Medicaments, 2007 (US$000s) 10
Hungarian Pharmaceutical Production, 1990-2005 (HUF billions) . 11
Egis ANDA Approvals, 2002-2005 . 14
Human Pharmaceuticals by Therapeutic Area, 2001-2005 (HUF millions) 14
Leading Products by Turnover, 2007/8 . 15
Egis Financial Results, 2002-2008 (HUF millions) . 15
Exports by Key Market, 2006-08 (US$000s) 15
Gedeon Richter, Main Licensing Partners, 2008 16
Product Sales by Therapeutic Group, 2002-2008 (%) 17
Gedeon Richter, Top Ten Products, 2007-2008 (HUF millions) 18
Gedeon Richter ANDA Approvals, 2002-2008 18
Gedeon Richter Financial Results, 2001-2008 (HUF millions) 18
Gedeon Richter, Top Ten Products in Hungary, 2007-2008 (HUF millions) . 19
Gedeon Richter Sales by Region, 2003-2008 (HUF millions) 20
Gedeon Richter Top Ten Export Markets, 2007-2008 (US$ millions) . 21
Exports of Pharmaceuticals, 2003-2007 (US$000s) . 24
Export Trends, 2006-2007 (US$000s) 24
Leading Destinations, 2007 (US$000s) . 25
Marketing Authorisation Fees, 2009 27
Pharmacies, 1997-2006 . 31
Summary of Demographic Data, 2006 & 2010 33
Projected Population, 2010-2015 . 33
Projected Health Expenditure, 2010-2015 . 38
Hospitals & Beds, 2006 39
HUNGARY PHARMA OUTLOOK
Pharma Outlook espicom BUSINESS INTELLIGENCE
iv Quarter I 2010
Projected Number of Physicians, 2010-2015 40
List of Charts
Radar Graph of the Hungarian Healthcare System 8
Gedeon Richter Products by Therapeutic Groups, 2008 (%) 17
Gedeon Richter Key Markets Breakdown, 2008 (%) 20
For full details, please email keithw@cmsinfo.com
Top of Page
Buy now!
Top of Page
|
|
